Monash IVF downgrades FY26 profit guidance on softer fertility volumes
Make us a preferred source
Make us a preferred source on Google
The news: Monash IVF has downgraded its FY26 underlying net profit after tax to between $17 million and $18 million, citing lower assisted reproductive technology (ART) activity in the second half.
The context: The company stated that Australian ART market cycle volumes fell 4.7% in the three months to April year-on-year, with the adverse impact expected to continue through May and June.
However, the company expanded its market share by 1% to 20.1% over the same period compared to the prior corresponding quarter. Due to these gains, Monash IVF projects its total full-year volumes to be materially higher driven by its international operations.
Monash also confirmed that operational and cost efficiently initiatives are underway, with financial benefits expected to flow through in FY27.
What they said: “Monash IVF has increased its Australian stimulated cycle market share during the period and has taken steps to reduce costs and improve operational performance,” CEO Victoria Atkinson said.
“These initiatives are expected to contribute more meaningfully in FY27,” she added.
The source: ASX
